Share

“Psychometric validation of the European Organisation for Research and Treatment of Cancer–Quality of Life Questionnaire Sexual Health (EORTC QLQ-SH22)”

New publication on EORTC QLQ-SH22 has been published in European Journal of Cancer.

Greimel E, Nagele E, Lanceley A, Oberguggenberger AS, Nordin A, Kuljanic K, Arraras JI, Wei-Chu C, Jensen PT, Tomaszewski KA, Creutzberg CL, Galalae R, Toelen H, Zimmermann K, Bjelic-Radisic V, Costantini A, Almont T, Serpentini S, Paskeviciute Frøding L, Vistad I, Schmalz C; EORTC Quality of Life Group.

Psychometric validation of the European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire Sexual Health (EORTC QLQ-SH22).

Abstract

Background: The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group developed a questionnaire to assess sexual health in patients with cancer and cancer survivors. This study evaluates the psychometric properties of the questionnaire.

Methods: The 22-item EORTC sexual health questionnaire (EORTC QLQ-SH22) was administered with the EORTC QLQ-C30 to 444 patients with cancer. The hypothesised scale structure, reliability and validity were evaluated through standardised psychometric procedures.

Results: The cross-cultural field study showed that the majority of patients (94.7%) were able to complete the QLQ-SH22 in less than 20 min; 89% of the study participants did not need any help to fill in the questionnaire. Multi-item multi-trait scaling analysis confirmed the hypothesised scale structure with two multi-item scales (sexual satisfaction, sexual pain) and 11 single items (including five conditional items and four gender-specific items). The internal consistency yielded acceptable Cronbach’s alpha coefficients (.90 for the sexual satisfaction scale, .80 for the sexual pain scale). The test-retest correlations (Pearson’s r) ranged from .70 to .93 except for the scale communication with professionals (.67) and male body image (.69). The QLQ-SH22 discriminates well between subgroups of patients differing in terms of their performance and treatment status.

Conclusion: The study supports the reliability, the content and construct validity of the QLQ-SH22. The newly developed questionnaire is clinically applicable to assess sexual health of patients with cancer at different treatment stages and during survivorship for clinical trials and for clinical practice.

Back to news list

Related News

  • New study validates clustering of QLQ-30 HRQoL scales, which can help symptom burden management and inform clinical trial design 

  • EORTC QLG Executive Committee – Call for Candidates

  • EORTC Quality of Life Group Open Access Policy

  • New QLG publication “Developing an e-learning course on the use of PRO measures in oncological practice: health care professionals’ preferences for learning content and methods”

  • “Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors”

  • “Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial”

  • “Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients”

  • “Minimally important differences for interpreting the EORTC QLQ-C30 in advanced colorectal cancer patients treated with chemotherapy”

  • UPDATE – 17-18 September 2020 Quality of Life Group Virtual Autumn meeting